Camille Wise, NP
Nurse Practitioner · Homer, LANPI 1013949213
Payments from drug & device makers
Across 98 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$217
- AstraZeneca$213
- Bayer$180
- AbbVie$113
- Lilly USA, LLC$97
- Paratek Pharmaceuticals, Inc.$74
- plus $826 from 21 others
What the payments were for
- Food & beverage$1,61694%
- Education$453%
- Gifts$593%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 13 | $217 |
| AstraZeneca | 7 | $213 |
| Bayer | 11 | $180 |
| AbbVie | 7 | $113 |
| Lilly USA, LLC | 5 | $97 |
| Paratek Pharmaceuticals, Inc. | 5 | $74 |
| GSK | 3 | $68 |
| Sunovion Pharmaceuticals Inc. | 6 | $67 |
| Sumitomo Pharma America, Inc. | 4 | $64 |
| Exact Sciences | 4 | $63 |
| Mannkind Corporation | 1 | $59 |
| Pfizer | 4 | $59 |
| Astellas Pharma US Inc | 3 | $55 |
| Novartis | 3 | $53 |
| Axsome Therapeutics, Inc. | 3 | $47 |
| Novo Nordisk | 3 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Shield Therapeutics Inc | 2 | $28 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $26 |
| Inogen, Inc. | 2 | $24 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| Abbott | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$117
How this compares
$1,721 in reported general payments places this provider in the 75th percentile of 969 nurse practitioner providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 37 | $47,166 |
| FarxigaDapagliflozin Propanediol | 60 | $46,947 |
| MounjaroTirzepatide | 35 | $36,726 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $27,332 |
| EliquisApixaban | 27 | $22,920 |
| LinzessLinaclotide | 32 | $20,675 |
| JanuviaSitagliptin Phosphate | 31 | $18,937 |
| MyrbetriqMirabegron | 29 | $13,155 |
| RybelsusSemaglutide | 13 | $12,205 |
| GlyxambiEmpagliflozin/Linagliptin | 14 | $8,273 |
| Repatha SureclickEvolocumab | 12 | $6,726 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $4,704 |
| Sucralfate | 43 | $2,741 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 89 | $2,479 |
| Lurasidone Hcl | 11 | $2,108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $43 | $59,37050 claims |
| AstraZenecaFarxiga | $213 | $46,94760 claims |
| Lilly USA, LLCMounjaro | $97 | $36,72635 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $68 | $32,03644 claims |
| PfizerEliquis | $59 | $22,92027 claims |
| AbbVieLinzess, Armour Thyroid | $113 | $22,19650 claims |
| MerckJanuvia | $217 | $18,93731 claims |
| Astellas Pharma US IncMyrbetriq | $55 | $13,15529 claims |
| Boehringer IngelheimGlyxambi | $14 | $8,27314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 969 nurse practitioner providers in Louisiana.
Other nurse practitioner in Homer
- Karen DeshotelLafayette$264K
- Christopher ManuelKaplan$145K
- Tammy BennettShreveport$99K
- Jessica BordelonHammond$78K
- Teri DugganBossier City$67K
- Matt LandryLafayette$50K
- Cynthia CobbLafayette$48K
- Ellen GentileWest Monroe$31K
- Reghan LittlepageAlexandria$24K
- April WoodrowOpelousas$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.